TOP TEN perturbations for O60635 (Homo sapiens)

Organism: Homo sapiens
Gene: O60635
Selected probe(set): 209114_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of O60635 (209114_at) across 5610 perturbations tested by GENEVESTIGATOR:

Barrett's esophagus study 3 / normal esophageal epithelium sample

Relative Expression (log2-ratio):5.818076
Number of Samples:17 / 18
Experimental Barrett's esophagus study 3
Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection.
Control normal esophageal epithelium sample
Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy.

prostate cancer study 8 (p. canc) / prostate cancer study 8 (ptasc)

Relative Expression (log2-ratio):5.790662
Number of Samples:3 / 2
Experimental prostate cancer study 8 (p. canc)
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (ptasc)
CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy.

Barrett's esophagus study 3 / esophageal squamous cell carcinoma study 1

Relative Expression (log2-ratio):4.6951427
Number of Samples:17 / 8
Experimental Barrett's esophagus study 3
Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection.
Control esophageal squamous cell carcinoma study 1
Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy.

ovarian tumor study 28 (clear cell adenocarcinoma) / ovarian tumor study 28 (adenocarcinoma)

Relative Expression (log2-ratio):4.2515287
Number of Samples:6 / 3
Experimental ovarian tumor study 28 (clear cell adenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with clear cell adenocarcinoma.
Control ovarian tumor study 28 (adenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with adenocarcinoma.

nephroblastoma study 2 / normal kidney tissue

Relative Expression (log2-ratio):-4.2327156
Number of Samples:4 / 3
Experimental nephroblastoma study 2
Tumor tissue samples from the kidney of patients with Wilms’ tumor.
Control normal kidney tissue
Normal adult kidney tissue samples.

prostate cancer study 8 (p. canc) / prostate cancer study 8 (psfmc)

Relative Expression (log2-ratio):3.990984
Number of Samples:3 / 5
Experimental prostate cancer study 8 (p. canc)
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (psfmc)
CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy.

colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)

Relative Expression (log2-ratio):-3.9834108
Number of Samples:24 / 3
Experimental colorectal cancer study 4 (recurring)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery.
Control adjacent colon tissue (recurring)
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up.

TGF-β study 12 / untreated NCI-H358 cell sample

Relative Expression (log2-ratio):-3.9056044
Number of Samples:3 / 3
Experimental TGF-β study 12
NCI-H358 cells were cultured for 2-3 weeks in the presence of 2ng/ml of TGF-β, to induce epithelial-mesenchymal transition (EMT). 24 hours prior analysis cells were re-seeded without TGF-β.
Control untreated NCI-H358 cell sample
NCI-H358 cells grown in standard media.

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)

Relative Expression (log2-ratio):3.8359175
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (confluent)
Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert.

colorectal cancer study 4 (non-recurring) / adjacent colon tissue (non-recurring)

Relative Expression (log2-ratio):-3.745535
Number of Samples:76 / 18
Experimental colorectal cancer study 4 (non-recurring)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients did not develop metastatic recurrence during follow-up after surgery.
Control adjacent colon tissue (non-recurring)
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). No metastatic recurrence during follow-up.